Can Ozempic Help With Addiction? What the First Clinical Trial Actually Shows
Written by Jakub Havelka
Software engineer · 10+ years in recovery · Author of the Craving Toolkit
People started noticing something strange. They'd begin weekly injections of semaglutide — marketed as Ozempic for diabetes and Wegovy for weight loss — and a few weeks in, they'd realize they didn't want to drink anymore. Not "trying not to drink." Not white-knuckling through happy hour. Just... the desire had dimmed. The pull was gone.
At first it was anecdotal. Reddit threads, patient reports, doctors quietly noting the pattern. Then the population studies came. A large Swedish health records analysis found that people with alcohol use disorder who were prescribed semaglutide had significantly lower hospitalization rates related to their drinking — reductions that exceeded those seen with medications actually approved for alcohol use disorder.
In early 2025, the first randomized, placebo-controlled clinical trial confirmed what the anecdotes had been suggesting. The results, published in JAMA Psychiatry, are preliminary but striking — and they raise a question that could reshape addiction treatment: what if one of the most effective tools against cravings was already sitting in millions of people's refrigerators?
What the trial found
The study, led by Christian Hendershot at USC's Institute for Addiction Science and Klara Klein at UNC School of Medicine, recruited 48 adults who met criteria for alcohol use disorder but weren't actively seeking treatment for it. Half received weekly injections of semaglutide at low doses (starting at 0.25 mg/week, increasing to 0.5 mg, then 1.0 mg in the final week). The other half received placebo.
Over nine weeks, those receiving semaglutide showed:
- Reduced alcohol craving throughout the trial
- Fewer drinks on days they did drink
- Greater reductions in heavy drinking days
- Lower alcohol consumption in controlled laboratory settings
The effect sizes were medium to large — and notably, they appeared to exceed those typically seen with naltrexone and acamprosate, the two most commonly prescribed FDA-approved medications for alcohol use disorder. This was at the lowest clinical doses of semaglutide. The participants weren't even on the standard weight-loss dose.
An unexpected bonus: among a small subgroup of smokers in the trial, those on semaglutide also reduced their cigarette consumption more than the placebo group. There are currently no approved medications that address both alcohol and nicotine cravings simultaneously.
Semaglutide didn't reduce the number of days people chose to drink — it reduced how much they drank when they did, and how much they craved it in between. That distinction matters. As one addiction psychiatrist noted, most people seeking treatment don't want lifelong abstinence as their goal. They want control. Semaglutide seems to offer something closer to that — a dimming of the compulsive pull rather than a forced stop.
How GLP-1 drugs might affect addiction
GLP-1 receptor agonists like semaglutide were designed to mimic a natural hormone called glucagon-like peptide-1, which regulates blood sugar, slows stomach emptying, and reduces appetite. Their popularity for weight loss is based on this appetite-suppression mechanism.
But GLP-1 receptors aren't only in the gut. They're also in the brain — specifically in areas involved in reward processing, motivation, and craving. The nucleus accumbens and the ventral tegmental area, two structures at the core of the [dopamine reward system](/articles/pleasure-pain-balance-explains-addiction), both express GLP-1 receptors. This means semaglutide doesn't just make you less hungry. It appears to modulate the same reward circuitry that drives addictive behavior.
The researchers think — and this is still being investigated — that GLP-1 receptor agonists may reduce the reward value of addictive substances by altering dopamine signaling in the mesolimbic pathway. In animal studies, GLP-1 agonists reduce dopamine release in the nucleus accumbens in response to alcohol and other drugs. Less dopamine surge means less reinforcement means less craving over time.
Think of it this way: the drug doesn't block your ability to enjoy things. It turns down the volume on the compulsive wanting — the "I need this now" signal that addiction amplifies beyond reason. The substance still registers, but the desperate pull weakens. For someone who's spent years feeling like a puppet controlled by their cravings, that shift in volume can be transformative.
What this doesn't mean
Before anyone calls their doctor demanding a prescription, some critical context:
This was a Phase 2 trial with 48 participants. That's tiny by clinical standards. Phase 2 trials are designed to determine whether a larger, more expensive Phase 3 trial is justified. The results are promising, not conclusive. Larger studies with hundreds or thousands of participants are needed — and several are already underway, including one at the NIH.
Semaglutide is not FDA-approved for addiction. Using it for alcohol use disorder is "off-label" — legal but not officially sanctioned. Prescribers can do it, but insurance probably won't cover it for this indication, and the safety profile specifically for people with addiction hasn't been fully established.
The participants weren't typical treatment-seekers. The trial population was 71% female, higher than average weight, and consuming less than typical treatment-seeking AUD patients (who often average 7-8+ drinks daily). Whether the results generalize to heavier drinkers, male-dominated populations, or people with other substance use disorders remains unknown.
Side effects are real. Nausea, the most common semaglutide side effect, was present in the trial. For someone already in the fragile early phase of recovery, persistent nausea could be destabilizing. The side effect profile at higher doses and over longer periods in addiction-specific populations hasn't been studied yet.
It doesn't address the underlying causes. Even if semaglutide reduces craving, it doesn't resolve the [trauma](/articles/trauma-and-addiction-gabor-mate), the unprocessed emotions, the environmental triggers, or the identity crisis that often drive addiction. A medication that quiets the craving without addressing what created it may be useful as a bridge — but it's unlikely to be sufficient as a standalone treatment.
Where this fits in the bigger picture
What's most interesting about the Ozempic-addiction connection isn't the specific drug. It's what it reveals about the nature of craving itself.
If a hormone that regulates appetite can also reduce the desire for alcohol, cocaine, nicotine, and potentially other addictive substances, it confirms something addiction neuroscience has been saying for years: all cravings — for food, drugs, gambling, sex, social media — run through overlapping neurochemical systems. The [narrowing effect](/articles/narrowing-effect-addiction) that Marc Lewis describes, the [pleasure-pain imbalance](/articles/pleasure-pain-balance-explains-addiction) that Anna Lembke explains — these frameworks predict that a drug modulating the reward system would affect multiple compulsive behaviors at once.
This also means that the GLP-1 story isn't just about one medication. It's about an entire class of drugs — and potentially future medications designed specifically to target reward-circuit modulation in addiction. If GLP-1 receptor agonists can reduce craving at low doses as a side effect, imagine what a compound designed for that purpose from the ground up could do.
For now, the practical takeaway is cautious optimism. Semaglutide isn't a cure for addiction. It isn't even an approved treatment yet. But it's the most interesting development in addiction pharmacology in years — and for the millions of people who've struggled with cravings that felt bigger than their ability to resist, the idea that the volume on those cravings could be chemically turned down is genuinely hopeful.
The cravings were never a sign of weakness. They were always neurochemistry. And neurochemistry can be changed.
Frequently Asked Questions
Does Ozempic reduce alcohol cravings? A 2025 clinical trial published in JAMA Psychiatry found that low-dose semaglutide (the active ingredient in Ozempic) reduced alcohol craving, drinks per drinking day, and heavy drinking days in adults with alcohol use disorder. The effects exceeded those typically seen with existing AUD medications, though larger trials are still needed.
Can Ozempic help with drug addiction? The clinical evidence so far is specific to alcohol and, in a small subgroup, nicotine. Animal studies suggest GLP-1 receptor agonists may reduce the rewarding effects of other substances including cocaine and opioids, but human clinical trials for these substances haven't been completed yet.
How does Ozempic affect the brain's reward system? GLP-1 receptors are present in brain regions central to reward and motivation, including the nucleus accumbens and ventral tegmental area. Semaglutide appears to modulate dopamine signaling in these areas, reducing the compulsive "wanting" signal without eliminating the capacity to experience pleasure.
Is Ozempic approved for treating addiction? No. As of 2026, semaglutide is FDA-approved only for type 2 diabetes (Ozempic) and obesity (Wegovy). Any use for addiction is off-label. Several larger clinical trials are underway to determine whether FDA approval for alcohol use disorder may be warranted.
Sources
- Hendershot CS, Bremmer MP, Paladino MB, et al. "Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial." JAMA Psychiatry. 2025;82(4):395-405. [PubMed](https://pubmed.ncbi.nlm.nih.gov/39937469/) - Lembke A. Dopamine Nation: Finding Balance in the Age of Indulgence. Dutton, 2021. - Klausen MK, et al. "GLP-1 receptor agonists and alcohol use disorder." JCI Insight. 2022;7(19):e159953.
About the Author
Jakub Havelka is a software engineer based in Europe with over a decade of personal recovery experience across multiple substances and behaviors. He built the Craving Toolkit from what actually helped — combining lived experience with research from Anna Lembke, Marc Lewis, Judson Brewer, Gabor Maté, and Charles Duhigg.
The Craving Toolkit provides the behavioral and psychological tools for managing cravings — from the [10-minute emergency protocol](/articles/survive-first-10-minutes-of-craving) to daily practices that rebuild your reward system. Medication and behavioral strategies aren't competing approaches — they're complementary.